Compare IOVA & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | POET |
|---|---|---|
| Founded | 2007 | 1972 |
| Country | United States | Canada |
| Employees | 975 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2008 | 2008 |
| Metric | IOVA | POET |
|---|---|---|
| Price | $3.42 | $14.91 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 13.7M | ★ 18.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.74 | $848.96 |
| Revenue Next Year | $40.31 | $700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $3.79 |
| 52 Week High | $5.63 | $12.95 |
| Indicator | IOVA | POET |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 81.68 |
| Support Level | $2.05 | $5.10 |
| Resistance Level | $4.33 | N/A |
| Average True Range (ATR) | 0.30 | 1.12 |
| MACD | -0.02 | 0.83 |
| Stochastic Oscillator | 22.44 | 94.15 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.